PortalPublikationenDown-Regulation of S100A8 is an Independent Predictor of PSA...

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy

Standard

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. / Minner, Sarah; Hager, Dominik; Steurer, Stefan; Höflmayer, Doris; Tsourlakis, Maria Christina; Möller-Koop, Christina; Clauditz, Till S; Hube-Magg, Claudia; Luebke, Andreas M; Simon, Ronald; Sauter, Guido; Göbel, Cosima; Weidemann, Sören; Lebok, Patrick; Dum, David; Fraune, Christoph; Izbicki, Jakob; Burandt, Eike; Schlomm, Thorsten; Huland, Hartwig; Heinzer, Hans; Haese, Alexander; Graefen, Markus; Heumann, Asmus.

in: NEOPLASIA, Jahrgang 21, Nr. 9, 09.2019, S. 872-881.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Minner, S, Hager, D, Steurer, S, Höflmayer, D, Tsourlakis, MC, Möller-Koop, C, Clauditz, TS, Hube-Magg, C, Luebke, AM, Simon, R, Sauter, G, Göbel, C, Weidemann, S, Lebok, P, Dum, D, Fraune, C, Izbicki, J, Burandt, E, Schlomm, T, Huland, H, Heinzer, H, Haese, A, Graefen, M & Heumann, A 2019, 'Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy', NEOPLASIA, Jg. 21, Nr. 9, S. 872-881. https://doi.org/10.1016/j.neo.2019.07.003

APA

Minner, S., Hager, D., Steurer, S., Höflmayer, D., Tsourlakis, M. C., Möller-Koop, C., Clauditz, T. S., Hube-Magg, C., Luebke, A. M., Simon, R., Sauter, G., Göbel, C., Weidemann, S., Lebok, P., Dum, D., Fraune, C., Izbicki, J., Burandt, E., Schlomm, T., ... Heumann, A. (2019). Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. NEOPLASIA, 21(9), 872-881. https://doi.org/10.1016/j.neo.2019.07.003

Vancouver

Minner S, Hager D, Steurer S, Höflmayer D, Tsourlakis MC, Möller-Koop C et al. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. NEOPLASIA. 2019 Sep;21(9):872-881. https://doi.org/10.1016/j.neo.2019.07.003

Bibtex

@article{6349b41cbb9d4ee4a2fb202a98e267ee,
title = "Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy",
abstract = "Dysregulation of S100A8 is described in many different human tumor types, but its role in prostate cancer is unknown. To evaluate the clinical relevance of S100A8 expression in prostate cancer, a tissue microarray containing 13,665 tumors was analyzed by immunohistochemistry. Cytoplasmic S100A8 staining was compared to prostate cancer phenotype, patient prognosis and molecular features including TMPRSS2:ERG fusion status and deletions of PTEN, 3p, 5q and 6q. S100A8 immunostaining was typically seen in normal prostate tissue but lost in 60% of 9786 interpretable prostate cancers. In the remaining tumors, S100A8 was considered weak in 17.9%, moderate in 17.8% and strong in 5.4% of cases. Loss of S100A8 expression was linked to advanced tumor stage, high Gleason grade, positive nodal status, positive surgical margin and high preoperative PSA (P < .0001 each). In addition, loss of S100A8 expression was associated with TMPRSS2:ERG fusions (P < .0001), deletions of PTEN, 3p, and 6q (P < .005), and a high number of genomic deletions per tumor (P = .0009). Absence of S100A8 immunostaining was also linked to an elevated risk for early PSA recurrence (P < .0001). In a multivariate analysis limited to features that are preoperatively available, the prognostic impact of S100A8 expression (P < .0001) was independent of clinical stage, Gleason grade, and serum PSA level (P < .0001). Taken together, the results of our study demonstrate that complete loss of S100A8 expression is linked to adverse tumor features and predicts early biochemical recurrence in prostate cancer. S100A8 measurement, either alone or in combination might be of clinical utility in prostate cancers.",
author = "Sarah Minner and Dominik Hager and Stefan Steurer and Doris H{\"o}flmayer and Tsourlakis, {Maria Christina} and Christina M{\"o}ller-Koop and Clauditz, {Till S} and Claudia Hube-Magg and Luebke, {Andreas M} and Ronald Simon and Guido Sauter and Cosima G{\"o}bel and S{\"o}ren Weidemann and Patrick Lebok and David Dum and Christoph Fraune and Jakob Izbicki and Eike Burandt and Thorsten Schlomm and Hartwig Huland and Hans Heinzer and Alexander Haese and Markus Graefen and Asmus Heumann",
note = "Copyright {\textcopyright} 2019 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2019",
month = sep,
doi = "10.1016/j.neo.2019.07.003",
language = "English",
volume = "21",
pages = "872--881",
journal = "NEOPLASIA",
issn = "1476-5586",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy

AU - Minner, Sarah

AU - Hager, Dominik

AU - Steurer, Stefan

AU - Höflmayer, Doris

AU - Tsourlakis, Maria Christina

AU - Möller-Koop, Christina

AU - Clauditz, Till S

AU - Hube-Magg, Claudia

AU - Luebke, Andreas M

AU - Simon, Ronald

AU - Sauter, Guido

AU - Göbel, Cosima

AU - Weidemann, Sören

AU - Lebok, Patrick

AU - Dum, David

AU - Fraune, Christoph

AU - Izbicki, Jakob

AU - Burandt, Eike

AU - Schlomm, Thorsten

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Haese, Alexander

AU - Graefen, Markus

AU - Heumann, Asmus

N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2019/9

Y1 - 2019/9

N2 - Dysregulation of S100A8 is described in many different human tumor types, but its role in prostate cancer is unknown. To evaluate the clinical relevance of S100A8 expression in prostate cancer, a tissue microarray containing 13,665 tumors was analyzed by immunohistochemistry. Cytoplasmic S100A8 staining was compared to prostate cancer phenotype, patient prognosis and molecular features including TMPRSS2:ERG fusion status and deletions of PTEN, 3p, 5q and 6q. S100A8 immunostaining was typically seen in normal prostate tissue but lost in 60% of 9786 interpretable prostate cancers. In the remaining tumors, S100A8 was considered weak in 17.9%, moderate in 17.8% and strong in 5.4% of cases. Loss of S100A8 expression was linked to advanced tumor stage, high Gleason grade, positive nodal status, positive surgical margin and high preoperative PSA (P < .0001 each). In addition, loss of S100A8 expression was associated with TMPRSS2:ERG fusions (P < .0001), deletions of PTEN, 3p, and 6q (P < .005), and a high number of genomic deletions per tumor (P = .0009). Absence of S100A8 immunostaining was also linked to an elevated risk for early PSA recurrence (P < .0001). In a multivariate analysis limited to features that are preoperatively available, the prognostic impact of S100A8 expression (P < .0001) was independent of clinical stage, Gleason grade, and serum PSA level (P < .0001). Taken together, the results of our study demonstrate that complete loss of S100A8 expression is linked to adverse tumor features and predicts early biochemical recurrence in prostate cancer. S100A8 measurement, either alone or in combination might be of clinical utility in prostate cancers.

AB - Dysregulation of S100A8 is described in many different human tumor types, but its role in prostate cancer is unknown. To evaluate the clinical relevance of S100A8 expression in prostate cancer, a tissue microarray containing 13,665 tumors was analyzed by immunohistochemistry. Cytoplasmic S100A8 staining was compared to prostate cancer phenotype, patient prognosis and molecular features including TMPRSS2:ERG fusion status and deletions of PTEN, 3p, 5q and 6q. S100A8 immunostaining was typically seen in normal prostate tissue but lost in 60% of 9786 interpretable prostate cancers. In the remaining tumors, S100A8 was considered weak in 17.9%, moderate in 17.8% and strong in 5.4% of cases. Loss of S100A8 expression was linked to advanced tumor stage, high Gleason grade, positive nodal status, positive surgical margin and high preoperative PSA (P < .0001 each). In addition, loss of S100A8 expression was associated with TMPRSS2:ERG fusions (P < .0001), deletions of PTEN, 3p, and 6q (P < .005), and a high number of genomic deletions per tumor (P = .0009). Absence of S100A8 immunostaining was also linked to an elevated risk for early PSA recurrence (P < .0001). In a multivariate analysis limited to features that are preoperatively available, the prognostic impact of S100A8 expression (P < .0001) was independent of clinical stage, Gleason grade, and serum PSA level (P < .0001). Taken together, the results of our study demonstrate that complete loss of S100A8 expression is linked to adverse tumor features and predicts early biochemical recurrence in prostate cancer. S100A8 measurement, either alone or in combination might be of clinical utility in prostate cancers.

U2 - 10.1016/j.neo.2019.07.003

DO - 10.1016/j.neo.2019.07.003

M3 - SCORING: Journal article

C2 - 31382165

VL - 21

SP - 872

EP - 881

JO - NEOPLASIA

JF - NEOPLASIA

SN - 1476-5586

IS - 9

ER -